Clinical Trials

Dec. 13, 2018

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR)

• Study Sponsor: Acceleron Pharma, Inc.
• Institution: Acceleron Pharma, Inc.
• Start Date: Wednesday, June 27, 2018
• End Date: Tuesday, March 31, 2020
• Design: 
  • Placebo-controlled
  • Background treatment allowed
• Age range (years): 18 to 125
• Type of PH
  • IPAH
  • Heritable – APAH
  • CTD – APAH
  • CHD – APAH
  • Toxic – APAH
• Study Duration for individual patient: 24 weeks
• Contact:  https://clinicaltrials.gov/ct2/show/NCT03496207